Swiss food conglomerate Nestle is reportedly expanding its skincare portfolio after acquiring various injectable treatment patents in a $1.4 billion deal.
Reports say Nestle acquired the rights for various wrinkle treatments from Valeant Pharmaceuticals.
While the deal allows Nestle to own the rights to treatments acquired when it fully took over its joint venture with Galderma, the transaction poses benefits for Valeant, as well. According to reports, the sale unloads a possible antitrust hurdle for Valeant, which is looking to acquire US Botox maker Allergan.
Some analysts, however, doubt that the acquisition will be as beneficial to Nestle as intended. The company has been looking for years to expand from a confectionary company into a global healthcare and nutrition brand; some experts, reports say, doubt that winkle treatment fits under that market.
Full content: International Business Times
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.